Antineoplastic agents used in pediatric hematopoietic bone marrow transplantation: a review about pharmacology and pharmaceutical issues.

Authors

  • Larissa Maria Hilsdorf Bernardi Barreto SOBRAFO
  • Rodrigo Spineli Macedo
  • Ana Carolina Sayuri Nagai
  • Ananda Vial Cobello
  • Haíssa Pereira Ramos Rodrigues

DOI:

https://doi.org/10.46765/2675-374X.2021v2n4p130

Keywords:

Chemoterapy, Chemotherapeutic agents, Bone Marrow Transplantation, Pediatrics

Abstract

This article proposes the characterization of the main chemotherapeutic agents used in hematopoietic stem cell transplantation in pediatric patients, carrying out a review of the main pharmacological and pharmacokinetic characteristics that are peculiar to children, as well as technical aspects for the handling, prescription, and administration of each one of these.

         It is extremely important that all professionals know how to recognize the characteristics of each drug and how its peculiarities impact the quality of patient's treatment, being able to predict and propose necessary interventions for potential problems of therapy, which can be identified and measured.

Downloads

Published

11/30/2021

How to Cite

Barreto, L. M. H. B., Rodrigo Spineli Macedo, Ana Carolina Sayuri Nagai, Ananda Vial Cobello, & Haíssa Pereira Ramos Rodrigues. (2021). Antineoplastic agents used in pediatric hematopoietic bone marrow transplantation: a review about pharmacology and pharmaceutical issues . JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2(4), 130. https://doi.org/10.46765/2675-374X.2021v2n4p130

Issue

Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Section

Original article

License

Copyright (c) 2021 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.